查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1587292

组合抗体疗法市场：按类型、适应症、给药途径、分销管道、最终用途分类 - 全球预测 2025-2030

Combination Antibody Therapy Market by Type (Antibody-Drug Conjugates, Bispecific Antibodies, Chemotherapy-Monoclonal Antibodies), Indication (Cancer, HIV), Route of Administration, Distribution Channel, End-Use - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 197 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年联合抗体治疗市值为2093.7亿美元，预计到2024年将达到2315.5亿美元，复合年增长率为9.30%，到2030年将达到3901.8亿美元。

联合抗体疗法是指使用两种或多种针对不同抗原或抗原表位的单株抗体来治疗各种疾病，特别是癌症、自体免疫疾病和感染疾病。这种方法旨在提高治疗效果，克服抗药性，并对病理目标提供多方面的攻击。对组合抗体疗法的需求源自于难以用单一药物治疗的复杂疾病的日益普及。联合治疗可以增强协同效应，减少抗药性，提高缓解率，从而满足重要的未满足的医疗需求。应用范围从肿瘤学到肿瘤生长、类风湿性关节炎等慢性疾病以及 COVID-19 等感染疾病的多种途径。最终用途范围包括从事开发先进治疗解决方案的医院、诊所和研究机构。

主要市场统计
基准年[2023] 2093.7亿美元
预测年份 [2024] 2315.5亿美元
预测年份 [2030] 3901.8亿美元
复合年增长率（%） 9.30%

联合抗体治疗市场的成长主要是由生物技术的进步和製药行业研发支出的增加以及慢性病和文明病盛行率的上升所推动的。治疗抗体管道的扩大和医疗保健支出的增加进一步推动了市场的发展。最近，个人化医疗和精准治疗的潜力已经成为一个机会。利用全面的患者资料分析来开发客製化的联合治疗可以显着改善治疗结果。对公司的建议包括投资伙伴关係和协作研究以加速创新，以及部署技术以简化研究方法。

儘管潜力巨大，但联合抗体治疗市场面临开发成本高、监管挑战、生产过程复杂以及免疫副作用风险等限制。值得探索的创新领域包括使用人工智慧来优化抗体选择和组合、新颖的递送机制以及预测治疗反应的预测模型。市场的特点是技术进步快、竞争激烈，需要灵活的策略来确保竞争优势。对新型抗体和免疫系统相互作用的持续研究对于维持这个充满活力和不断发展的领域的业务成长至关重要。

市场动态：揭示快速发展的组合抗体疗法市场的关键市场洞察

供需的动态交互作用正在改变联合抗体治疗市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时消费行为及其对製造成本的影响以及对采购趋势的影响。

  • 市场驱动因素
    • 全球癌症患者数量增加
    • 改善治疗和患者治疗效果的需求日益增长
    • 用于抗药性管理
  • 市场限制因素
    • 联合抗体疗法的高成本和复杂性
  • 市场机会
    • 联合抗体疗法的持续研究和临床测试
    • 个人化医疗方法的新用途
  • 市场问题
    • 与联合抗体疗法相关的副作用

波特五力：驾驭联合抗体治疗市场的策略工具

波特的五力框架是了解组合抗体疗法市场竞争格局的关键工具。波特的五力框架描述了评估公司竞争和探索策略机会的清晰方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解联合抗体治疗市场的外部影响

外部宏观环境因素在塑造联合抗体治疗市场的表现动态发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助企业预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析：了解联合抗体治疗市场的竞争格局

组合抗体疗法市场的详细市场占有率分析可以对供应商的绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、细分和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV定位矩阵组合抗体治疗市场供应商绩效评估

FPNV定位矩阵是评估合併抗体治疗市场供应商的关键工具。此矩阵允许业务组织根据供应商的商务策略和产品满意度评估供应商，从而做出符合其目标的明智决策。这四个象限使您能够清晰、准确地划分供应商，以确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议：在联合抗体疗法市场中製定成功之路

联合抗体治疗市场的策略分析对于旨在加强其在全球市场的影响力的公司至关重要。透过考虑关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机并取得长期成功。

该报告对涵盖关键焦点细分市场的市场进行了全面分析。

1. 市场渗透率：详细检视当前市场环境、主要企业的广泛资料、评估其在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有细分市场的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、主要产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策。

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品和地区提供最佳投资机会？

3.塑造市场的关键技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 世界各地的癌症患者数量正在增加。
      • 改善治疗和患者治疗效果的需求日益增加
      • 用于抗药性管理
    • 抑制因素
      • 联合抗体疗法的高成本和复杂性
    • 机会
      • 联合抗体疗法的持续研究和临床测试
      • 个人化医疗方法的新用途
    • 任务
      • 与联合抗体疗法相关的不良反应
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治
    • 经济
    • 社会
    • 科技
    • 法律
    • 环境

第六章 组合抗体治疗市场：依类型

  • 介绍
  • 抗体药物偶联物
  • 双特异性抗体
  • 化疗单株抗体

第七章 合併抗体治疗市场：依适应症分类

  • 介绍
  • 癌症
    • 血癌
    • 乳癌
    • 大肠直肠癌
    • 肺癌
  • HIV

第八章 组合抗体治疗市场：依给药途径

  • 介绍
  • 口服
  • 胃肠外的

第九章组合抗体治疗市场：按分销管道

  • 介绍
  • 医院药房
  • 网路药房
  • 零售药房

第10章组合抗体治疗市场：依最终用途

  • 介绍
  • 居家医疗
  • 医院
  • 专业中心

第十一章美洲联合抗体治疗市场

  • 介绍
  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十二章亚太联合抗体治疗市场

  • 介绍
  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十三章欧洲、中东和非洲的联合抗体治疗市场

  • 介绍
  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第14章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • AbbVie Inc.
  • Amgen Inc.
  • Argenx SE
  • AstraZeneca PLC
  • Atreca, Inc.
  • Bayer AG
  • BeiGene, Ltd.
  • Biogen Inc.
  • BioNTech SE
  • Boehringer Ingelheim International GmbH
  • Bristol Myers Squibb Company
  • CStone Pharmaceuticals
  • Eli Lilly and Company
  • Five Prime Therapeutics, Inc.
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • I-Mab Biopharma Co., Ltd.
  • IGM Biosciences, Inc.
  • Incyte Corporation
  • Janssen Pharmaceuticals, Inc. by Johnson & Johnson Service Inc.
  • Jazz Pharmaceuticals plc
  • Kyowa Kirin Co., Ltd.
  • MacroGenics, Inc.
  • Merck & Co., Inc.
  • MorphoSys AG
  • NBE-Therapeutics AG
  • Novartis AG
  • Pfizer Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Roche Holding AG
  • Sanofi SA
  • Sutro Biopharma, Inc.
  • Takeda Pharmaceutical Company Limited
  • Trillium Therapeutics Inc.
  • Xencor, Inc.
  • Zymeworks Inc.
Product Code: MRR-DD0700E81E99

The Combination Antibody Therapy Market was valued at USD 209.37 billion in 2023, expected to reach USD 231.55 billion in 2024, and is projected to grow at a CAGR of 9.30%, to USD 390.18 billion by 2030.

Combination antibody therapy refers to the use of two or more monoclonal antibodies to target different antigens or epitopes to treat various diseases, particularly cancer, autoimmune, and infectious diseases. This approach aims to enhance therapeutic efficacy, overcome resistance, and provide a multifaceted attack on pathological targets. The necessity for combination antibody therapy arises from the increasing prevalence of complex diseases that challenge single-agent treatments. Combination therapy allows for enhanced synergistic effects, reduced drug resistance, and improved response rates, thereby meeting critical unmet medical needs. Its application spans oncology, where it is used to target multiple pathways involved in tumor growth, as well as in chronic diseases like rheumatoid arthritis and infectious diseases like COVID-19. The end-use scope includes hospitals, clinics, and research institutes engaged in developing advanced therapeutic solutions.

KEY MARKET STATISTICS
Base Year [2023] USD 209.37 billion
Estimated Year [2024] USD 231.55 billion
Forecast Year [2030] USD 390.18 billion
CAGR (%) 9.30%

The growth of the combination antibody therapy market is primarily driven by advancements in biotechnology and increased R&D spending in the pharmaceutical sector, coupled with a rising prevalence of chronic and lifestyle-associated diseases. An expanding pipeline of therapeutic antibodies and increasing healthcare expenditure further fuel the market. Lately, the potential for personalized medicine and precision treatment has emerged as an opportunity; leveraging comprehensive patient data analytics to develop tailored combination therapies could significantly enhance outcomes. Recommendations for companies include investing in partnerships and collaborations to accelerate innovation and adopting technology to streamline research processes.

Despite its promising potential, the combination antibody therapy market faces limitations such as high development costs, regulatory challenges, complex production processes, and the risk of adverse immunological responses. Innovative areas to explore include the use of artificial intelligence to optimize antibody selection and combination, novel delivery mechanisms, and predictive modeling to anticipate therapeutic responses. The market is characterized by rapid technological advancements and intense competition, necessitating agile strategies to secure a competitive edge. Continued research into novel antibodies and immune system interactions will be crucial for sustaining business growth in this dynamic and evolving field.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Combination Antibody Therapy Market

The Combination Antibody Therapy Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising number of cancer cases worldwide
    • Growing need to enhance treatment and patient outcomes
    • Utilization for drug resistance management
  • Market Restraints
    • High cost and complexity of combination antibody therapy
  • Market Opportunities
    • Ongoing research and clinical trials for combination antibody therapy
    • Emerging use of personalized medicine approach
  • Market Challenges
    • Adverse effects associated with combination antibody therapy

Porter's Five Forces: A Strategic Tool for Navigating the Combination Antibody Therapy Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Combination Antibody Therapy Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Combination Antibody Therapy Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Combination Antibody Therapy Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Combination Antibody Therapy Market

A detailed market share analysis in the Combination Antibody Therapy Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Combination Antibody Therapy Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Combination Antibody Therapy Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Combination Antibody Therapy Market

A strategic analysis of the Combination Antibody Therapy Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Combination Antibody Therapy Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Amgen Inc., Argenx SE, AstraZeneca PLC, Atreca, Inc., Bayer AG, BeiGene, Ltd., Biogen Inc., BioNTech SE, Boehringer Ingelheim International GmbH, Bristol Myers Squibb Company, CStone Pharmaceuticals, Eli Lilly and Company, Five Prime Therapeutics, Inc., Gilead Sciences, Inc., GlaxoSmithKline plc, I-Mab Biopharma Co., Ltd., IGM Biosciences, Inc., Incyte Corporation, Janssen Pharmaceuticals, Inc. by Johnson & Johnson Service Inc., Jazz Pharmaceuticals plc, Kyowa Kirin Co., Ltd., MacroGenics, Inc., Merck & Co., Inc., MorphoSys AG, NBE-Therapeutics AG, Novartis AG, Pfizer Inc., Regeneron Pharmaceuticals, Inc., Roche Holding AG, Sanofi S.A., Sutro Biopharma, Inc., Takeda Pharmaceutical Company Limited, Trillium Therapeutics Inc., Xencor, Inc., and Zymeworks Inc..

Market Segmentation & Coverage

This research report categorizes the Combination Antibody Therapy Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Type, market is studied across Antibody-Drug Conjugates, Bispecific Antibodies, and Chemotherapy-Monoclonal Antibodies.
  • Based on Indication, market is studied across Cancer and HIV. The Cancer is further studied across Blood Cancer, Breast Cancer, Colorectal Cancer, and Lung Cancer.
  • Based on Route of Administration, market is studied across Oral and Parenteral.
  • Based on Distribution Channel, market is studied across Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy.
  • Based on End-Use, market is studied across Homecare, Hospitals, and Specialty Centres.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising number of cancer cases worldwide
      • 5.1.1.2. Growing need to enhance treatment and patient outcomes
      • 5.1.1.3. Utilization for drug resistance management
    • 5.1.2. Restraints
      • 5.1.2.1. High cost and complexity of combination antibody therapy
    • 5.1.3. Opportunities
      • 5.1.3.1. Ongoing research and clinical trials for combination antibody therapy
      • 5.1.3.2. Emerging use of personalized medicine approach
    • 5.1.4. Challenges
      • 5.1.4.1. Adverse effects associated with combination antibody therapy
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Combination Antibody Therapy Market, by Type

  • 6.1. Introduction
  • 6.2. Antibody-Drug Conjugates
  • 6.3. Bispecific Antibodies
  • 6.4. Chemotherapy-Monoclonal Antibodies

7. Combination Antibody Therapy Market, by Indication

  • 7.1. Introduction
  • 7.2. Cancer
    • 7.2.1. Blood Cancer
    • 7.2.2. Breast Cancer
    • 7.2.3. Colorectal Cancer
    • 7.2.4. Lung Cancer
  • 7.3. HIV

8. Combination Antibody Therapy Market, by Route of Administration

  • 8.1. Introduction
  • 8.2. Oral
  • 8.3. Parenteral

9. Combination Antibody Therapy Market, by Distribution Channel

  • 9.1. Introduction
  • 9.2. Hospital Pharmacy
  • 9.3. Online Pharmacy
  • 9.4. Retail Pharmacy

10. Combination Antibody Therapy Market, by End-Use

  • 10.1. Introduction
  • 10.2. Homecare
  • 10.3. Hospitals
  • 10.4. Specialty Centres

11. Americas Combination Antibody Therapy Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific Combination Antibody Therapy Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa Combination Antibody Therapy Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2023
  • 14.2. FPNV Positioning Matrix, 2023
  • 14.3. Competitive Scenario Analysis
  • 14.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AbbVie Inc.
  • 2. Amgen Inc.
  • 3. Argenx SE
  • 4. AstraZeneca PLC
  • 5. Atreca, Inc.
  • 6. Bayer AG
  • 7. BeiGene, Ltd.
  • 8. Biogen Inc.
  • 9. BioNTech SE
  • 10. Boehringer Ingelheim International GmbH
  • 11. Bristol Myers Squibb Company
  • 12. CStone Pharmaceuticals
  • 13. Eli Lilly and Company
  • 14. Five Prime Therapeutics, Inc.
  • 15. Gilead Sciences, Inc.
  • 16. GlaxoSmithKline plc
  • 17. I-Mab Biopharma Co., Ltd.
  • 18. IGM Biosciences, Inc.
  • 19. Incyte Corporation
  • 20. Janssen Pharmaceuticals, Inc. by Johnson & Johnson Service Inc.
  • 21. Jazz Pharmaceuticals plc
  • 22. Kyowa Kirin Co., Ltd.
  • 23. MacroGenics, Inc.
  • 24. Merck & Co., Inc.
  • 25. MorphoSys AG
  • 26. NBE-Therapeutics AG
  • 27. Novartis AG
  • 28. Pfizer Inc.
  • 29. Regeneron Pharmaceuticals, Inc.
  • 30. Roche Holding AG
  • 31. Sanofi S.A.
  • 32. Sutro Biopharma, Inc.
  • 33. Takeda Pharmaceutical Company Limited
  • 34. Trillium Therapeutics Inc.
  • 35. Xencor, Inc.
  • 36. Zymeworks Inc.

LIST OF FIGURES

  • FIGURE 1. COMBINATION ANTIBODY THERAPY MARKET RESEARCH PROCESS
  • FIGURE 2. COMBINATION ANTIBODY THERAPY MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL COMBINATION ANTIBODY THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL COMBINATION ANTIBODY THERAPY MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL COMBINATION ANTIBODY THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL COMBINATION ANTIBODY THERAPY MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL COMBINATION ANTIBODY THERAPY MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL COMBINATION ANTIBODY THERAPY MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL COMBINATION ANTIBODY THERAPY MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL COMBINATION ANTIBODY THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL COMBINATION ANTIBODY THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL COMBINATION ANTIBODY THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL COMBINATION ANTIBODY THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL COMBINATION ANTIBODY THERAPY MARKET SIZE, BY END-USE, 2023 VS 2030 (%)
  • FIGURE 15. GLOBAL COMBINATION ANTIBODY THERAPY MARKET SIZE, BY END-USE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. AMERICAS COMBINATION ANTIBODY THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. AMERICAS COMBINATION ANTIBODY THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. UNITED STATES COMBINATION ANTIBODY THERAPY MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 19. UNITED STATES COMBINATION ANTIBODY THERAPY MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC COMBINATION ANTIBODY THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. ASIA-PACIFIC COMBINATION ANTIBODY THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA COMBINATION ANTIBODY THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 23. EUROPE, MIDDLE EAST & AFRICA COMBINATION ANTIBODY THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 24. COMBINATION ANTIBODY THERAPY MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 25. COMBINATION ANTIBODY THERAPY MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. COMBINATION ANTIBODY THERAPY MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL COMBINATION ANTIBODY THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL COMBINATION ANTIBODY THERAPY MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL COMBINATION ANTIBODY THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. COMBINATION ANTIBODY THERAPY MARKET DYNAMICS
  • TABLE 7. GLOBAL COMBINATION ANTIBODY THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL COMBINATION ANTIBODY THERAPY MARKET SIZE, BY ANTIBODY-DRUG CONJUGATES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL COMBINATION ANTIBODY THERAPY MARKET SIZE, BY BISPECIFIC ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL COMBINATION ANTIBODY THERAPY MARKET SIZE, BY CHEMOTHERAPY-MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL COMBINATION ANTIBODY THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL COMBINATION ANTIBODY THERAPY MARKET SIZE, BY CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL COMBINATION ANTIBODY THERAPY MARKET SIZE, BY BLOOD CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL COMBINATION ANTIBODY THERAPY MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL COMBINATION ANTIBODY THERAPY MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL COMBINATION ANTIBODY THERAPY MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL COMBINATION ANTIBODY THERAPY MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL COMBINATION ANTIBODY THERAPY MARKET SIZE, BY HIV, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL COMBINATION ANTIBODY THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL COMBINATION ANTIBODY THERAPY MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL COMBINATION ANTIBODY THERAPY MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL COMBINATION ANTIBODY THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL COMBINATION ANTIBODY THERAPY MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL COMBINATION ANTIBODY THERAPY MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL COMBINATION ANTIBODY THERAPY MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL COMBINATION ANTIBODY THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL COMBINATION ANTIBODY THERAPY MARKET SIZE, BY HOMECARE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL COMBINATION ANTIBODY THERAPY MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL COMBINATION ANTIBODY THERAPY MARKET SIZE, BY SPECIALTY CENTRES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. AMERICAS COMBINATION ANTIBODY THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 31. AMERICAS COMBINATION ANTIBODY THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 32. AMERICAS COMBINATION ANTIBODY THERAPY MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 33. AMERICAS COMBINATION ANTIBODY THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 34. AMERICAS COMBINATION ANTIBODY THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 35. AMERICAS COMBINATION ANTIBODY THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 36. AMERICAS COMBINATION ANTIBODY THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 37. ARGENTINA COMBINATION ANTIBODY THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 38. ARGENTINA COMBINATION ANTIBODY THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 39. ARGENTINA COMBINATION ANTIBODY THERAPY MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 40. ARGENTINA COMBINATION ANTIBODY THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 41. ARGENTINA COMBINATION ANTIBODY THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 42. ARGENTINA COMBINATION ANTIBODY THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 43. BRAZIL COMBINATION ANTIBODY THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 44. BRAZIL COMBINATION ANTIBODY THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 45. BRAZIL COMBINATION ANTIBODY THERAPY MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 46. BRAZIL COMBINATION ANTIBODY THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 47. BRAZIL COMBINATION ANTIBODY THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 48. BRAZIL COMBINATION ANTIBODY THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 49. CANADA COMBINATION ANTIBODY THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 50. CANADA COMBINATION ANTIBODY THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 51. CANADA COMBINATION ANTIBODY THERAPY MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 52. CANADA COMBINATION ANTIBODY THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 53. CANADA COMBINATION ANTIBODY THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 54. CANADA COMBINATION ANTIBODY THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 55. MEXICO COMBINATION ANTIBODY THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 56. MEXICO COMBINATION ANTIBODY THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 57. MEXICO COMBINATION ANTIBODY THERAPY MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 58. MEXICO COMBINATION ANTIBODY THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 59. MEXICO COMBINATION ANTIBODY THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 60. MEXICO COMBINATION ANTIBODY THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 61. UNITED STATES COMBINATION ANTIBODY THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. UNITED STATES COMBINATION ANTIBODY THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 63. UNITED STATES COMBINATION ANTIBODY THERAPY MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 64. UNITED STATES COMBINATION ANTIBODY THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 65. UNITED STATES COMBINATION ANTIBODY THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 66. UNITED STATES COMBINATION ANTIBODY THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 67. UNITED STATES COMBINATION ANTIBODY THERAPY MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 68. ASIA-PACIFIC COMBINATION ANTIBODY THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 69. ASIA-PACIFIC COMBINATION ANTIBODY THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 70. ASIA-PACIFIC COMBINATION ANTIBODY THERAPY MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 71. ASIA-PACIFIC COMBINATION ANTIBODY THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 72. ASIA-PACIFIC COMBINATION ANTIBODY THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 73. ASIA-PACIFIC COMBINATION ANTIBODY THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 74. ASIA-PACIFIC COMBINATION ANTIBODY THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 75. AUSTRALIA COMBINATION ANTIBODY THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. AUSTRALIA COMBINATION ANTIBODY THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 77. AUSTRALIA COMBINATION ANTIBODY THERAPY MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 78. AUSTRALIA COMBINATION ANTIBODY THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 79. AUSTRALIA COMBINATION ANTIBODY THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 80. AUSTRALIA COMBINATION ANTIBODY THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 81. CHINA COMBINATION ANTIBODY THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. CHINA COMBINATION ANTIBODY THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 83. CHINA COMBINATION ANTIBODY THERAPY MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 84. CHINA COMBINATION ANTIBODY THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 85. CHINA COMBINATION ANTIBODY THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 86. CHINA COMBINATION ANTIBODY THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 87. INDIA COMBINATION ANTIBODY THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 88. INDIA COMBINATION ANTIBODY THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 89. INDIA COMBINATION ANTIBODY THERAPY MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 90. INDIA COMBINATION ANTIBODY THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 91. INDIA COMBINATION ANTIBODY THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 92. INDIA COMBINATION ANTIBODY THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 93. INDONESIA COMBINATION ANTIBODY THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. INDONESIA COMBINATION ANTIBODY THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 95. INDONESIA COMBINATION ANTIBODY THERAPY MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 96. INDONESIA COMBINATION ANTIBODY THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 97. INDONESIA COMBINATION ANTIBODY THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 98. INDONESIA COMBINATION ANTIBODY THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 99. JAPAN COMBINATION ANTIBODY THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. JAPAN COMBINATION ANTIBODY THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 101. JAPAN COMBINATION ANTIBODY THERAPY MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 102. JAPAN COMBINATION ANTIBODY THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 103. JAPAN COMBINATION ANTIBODY THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 104. JAPAN COMBINATION ANTIBODY THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 105. MALAYSIA COMBINATION ANTIBODY THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 106. MALAYSIA COMBINATION ANTIBODY THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 107. MALAYSIA COMBINATION ANTIBODY THERAPY MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 108. MALAYSIA COMBINATION ANTIBODY THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 109. MALAYSIA COMBINATION ANTIBODY THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 110. MALAYSIA COMBINATION ANTIBODY THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 111. PHILIPPINES COMBINATION ANTIBODY THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 112. PHILIPPINES COMBINATION ANTIBODY THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 113. PHILIPPINES COMBINATION ANTIBODY THERAPY MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 114. PHILIPPINES COMBINATION ANTIBODY THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 115. PHILIPPINES COMBINATION ANTIBODY THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 116. PHILIPPINES COMBINATION ANTIBODY THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 117. SINGAPORE COMBINATION ANTIBODY THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 118. SINGAPORE COMBINATION ANTIBODY THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 119. SINGAPORE COMBINATION ANTIBODY THERAPY MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 120. SINGAPORE COMBINATION ANTIBODY THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 121. SINGAPORE COMBINATION ANTIBODY THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 122. SINGAPORE COMBINATION ANTIBODY THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 123. SOUTH KOREA COMBINATION ANTIBODY THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 124. SOUTH KOREA COMBINATION ANTIBODY THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 125. SOUTH KOREA COMBINATION ANTIBODY THERAPY MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 126. SOUTH KOREA COMBINATION ANTIBODY THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 127. SOUTH KOREA COMBINATION ANTIBODY THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 128. SOUTH KOREA COMBINATION ANTIBODY THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 129. TAIWAN COMBINATION ANTIBODY THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 130. TAIWAN COMBINATION ANTIBODY THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 131. TAIWAN COMBINATION ANTIBODY THERAPY MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 132. TAIWAN COMBINATION ANTIBODY THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 133. TAIWAN COMBINATION ANTIBODY THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 134. TAIWAN COMBINATION ANTIBODY THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 135. THAILAND COMBINATION ANTIBODY THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 136. THAILAND COMBINATION ANTIBODY THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 137. THAILAND COMBINATION ANTIBODY THERAPY MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 138. THAILAND COMBINATION ANTIBODY THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 139. THAILAND COMBINATION ANTIBODY THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 140. THAILAND COMBINATION ANTIBODY THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 141. VIETNAM COMBINATION ANTIBODY THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 142. VIETNAM COMBINATION ANTIBODY THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 143. VIETNAM COMBINATION ANTIBODY THERAPY MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 144. VIETNAM COMBINATION ANTIBODY THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 145. VIETNAM COMBINATION ANTIBODY THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 146. VIETNAM COMBINATION ANTIBODY THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 147. EUROPE, MIDDLE EAST & AFRICA COMBINATION ANTIBODY THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 148. EUROPE, MIDDLE EAST & AFRICA COMBINATION ANTIBODY THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 149. EUROPE, MIDDLE EAST & AFRICA COMBINATION ANTIBODY THERAPY MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 150. EUROPE, MIDDLE EAST & AFRICA COMBINATION ANTIBODY THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 151. EUROPE, MIDDLE EAST & AFRICA COMBINATION ANTIBODY THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 152. EUROPE, MIDDLE EAST & AFRICA COMBINATION ANTIBODY THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 153. EUROPE, MIDDLE EAST & AFRICA COMBINATION ANTIBODY THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 154. DENMARK COMBINATION ANTIBODY THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 155. DENMARK COMBINATION ANTIBODY THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 156. DENMARK COMBINATION ANTIBODY THERAPY MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 157. DENMARK COMBINATION ANTIBODY THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 158. DENMARK COMBINATION ANTIBODY THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 159. DENMARK COMBINATION ANTIBODY THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 160. EGYPT COMBINATION ANTIBODY THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 161. EGYPT COMBINATION ANTIBODY THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 162. EGYPT COMBINATION ANTIBODY THERAPY MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 163. EGYPT COMBINATION ANTIBODY THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 164. EGYPT COMBINATION ANTIBODY THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 165. EGYPT COMBINATION ANTIBODY THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 166. FINLAND COMBINATION ANTIBODY THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 167. FINLAND COMBINATION ANTIBODY THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 168. FINLAND COMBINATION ANTIBODY THERAPY MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 169. FINLAND COMBINATION ANTIBODY THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 170. FINLAND COMBINATION ANTIBODY THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 171. FINLAND COMBINATION ANTIBODY THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 172. FRANCE COMBINATION ANTIBODY THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 173. FRANCE COMBINATION ANTIBODY THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 174. FRANCE COMBINATION ANTIBODY THERAPY MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 175. FRANCE COMBINATION ANTIBODY THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 176. FRANCE COMBINATION ANTIBODY THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 177. FRANCE COMBINATION ANTIBODY THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 178. GERMANY COMBINATION ANTIBODY THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 179. GERMANY COMBINATION ANTIBODY THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 180. GERMANY COMBINATION ANTIBODY THERAPY MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 181. GERMANY COMBINATION ANTIBODY THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 182. GERMANY COMBINATION ANTIBODY THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 183. GERMANY COMBINATION ANTIBODY THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 184. ISRAEL COMBINATION ANTIBODY THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 185. ISRAEL COMBINATION ANTIBODY THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 186. ISRAEL COMBINATION ANTIBODY THERAPY MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 187. ISRAEL COMBINATION ANTIBODY THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 188. ISRAEL COMBINATION ANTIBODY THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 189. ISRAEL COMBINATION ANTIBODY THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 190. ITALY COMBINATION ANTIBODY THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 191. ITALY COMBINATION ANTIBODY THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 192. ITALY COMBINATION ANTIBODY THERAPY MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 193. ITALY COMBINATION ANTIBODY THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 194. ITALY COMBINATION ANTIBODY THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 195. ITALY COMBINATION ANTIBODY THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 196. NETHERLANDS COMBINATION ANTIBODY THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 197. NETHERLANDS COMBINATION ANTIBODY THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 198. NETHERLANDS COMBINATION ANTIBODY THERAPY MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 199. NETHERLANDS COMBINATION ANTIBODY THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 200. NETHERLANDS COMBINATION ANTIBODY THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 201. NETHERLANDS COMBINATION ANTIBODY THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 202. NIGERIA COMBINATION ANTIBODY THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 203. NIGERIA COMBINATION ANTIBODY THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 204. NIGERIA COMBINATION ANTIBODY THERAPY MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 205. NIGERIA COMBINATION ANTIBODY THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 206. NIGERIA COMBINATION ANTIBODY THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 207. NIGERIA COMBINATION ANTIBODY THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 208. NORWAY COMBINATION ANTIBODY THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 209. NORWAY COMBINATION ANTIBODY THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 210. NORWAY COMBINATION ANTIBODY THERAPY MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 211. NORWAY COMBINATION ANTIBODY THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 212. NORWAY COMBINATION ANTIBODY THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 213. NORWAY COMBINATION ANTIBODY THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 214. POLAND COMBINATION ANTIBODY THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 215. POLAND COMBINATION ANTIBODY THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 216. POLAND COMBINATION ANTIBODY THERAPY MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 217. POLAND COMBINATION ANTIBODY THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 218. POLAND COMBINATION ANTIBODY THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 219. POLAND COMBINATION ANTIBODY THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 220. QATAR COMBINATION ANTIBODY THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 221. QATAR COMBINATION ANTIBODY THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 222. QATAR COMBINATION ANTIBODY THERAPY MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 223. QATAR COMBINATION ANTIBODY THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 224. QATAR COMBINATION ANTIBODY THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 225. QATAR COMBINATION ANTIBODY THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 226. RUSSIA COMBINATION ANTIBODY THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 227. RUSSIA COMBINATION ANTIBODY THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 228. RUSSIA COMBINATION ANTIBODY THERAPY MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 229. RUSSIA COMBINATION ANTIBODY THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 230. RUSSIA COMBINATION ANTIBODY THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 231. RUSSIA COMBINATION ANTIBODY THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 232. SAUDI ARABIA COMBINATION ANTIBODY THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 233. SAUDI ARABIA COMBINATION ANTIBODY THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 234. SAUDI ARABIA COMBINATION ANTIBODY THERAPY MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 235. SAUDI ARABIA COMBINATION ANTIBODY THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 236. SAUDI ARABIA COMBINATION ANTIBODY THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 237. SAUDI ARABIA COMBINATION ANTIBODY THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 238. SOUTH AFRICA COMBINATION ANTIBODY THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 239. SOUTH AFRICA COMBINATION ANTIBODY THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 240. SOUTH AFRICA COMBINATION ANTIBODY THERAPY MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 241. SOUTH AFRICA COMBINATION ANTIBODY THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 242. SOUTH AFRICA COMBINATION ANTIBODY THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 243. SOUTH AFRICA COMBINATION ANTIBODY THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 244. SPAIN COMBINATION ANTIBODY THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 245. SPAIN COMBINATION ANTIBODY THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 246. SPAIN COMBINATION ANTIBODY THERAPY MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 247. SPAIN COMBINATION ANTIBODY THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 248. SPAIN COMBINATION ANTIBODY THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 249. SPAIN COMBINATION ANTIBODY THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 250. SWEDEN COMBINATION ANTIBODY THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 251. SWEDEN COMBINATION ANTIBODY THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 252. SWEDEN COMBINATION ANTIBODY THERAPY MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 253. SWEDEN COMBINATION ANTIBODY THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 254. SWEDEN COMBINATION ANTIBODY THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 255. SWEDEN COMBINATION ANTIBODY THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 256. SWITZERLAND COMBINATION ANTIBODY THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 257. SWITZERLAND COMBINATION ANTIBODY THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 258. SWITZERLAND COMBINATION ANTIBODY THERAPY MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 259. SWITZERLAND COMBINATION ANTIBODY THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 260. SWITZERLAND COMBINATION ANTIBODY THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 261. SWITZERLAND COMBINATION ANTIBODY THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 262. TURKEY COMBINATION ANTIBODY THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 263. TURKEY COMBINATION ANTIBODY THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 264. TURKEY COMBINATION ANTIBODY THERAPY MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 265. TURKEY COMBINATION ANTIBODY THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 266. TURKEY COMBINATION ANTIBODY THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 267. TURKEY COMBINATION ANTIBODY THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 268. UNITED ARAB EMIRATES COMBINATION ANTIBODY THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 269. UNITED ARAB EMIRATES COMBINATION ANTIBODY THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 270. UNITED ARAB EMIRATES COMBINATION ANTIBODY THERAPY MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 271. UNITED ARAB EMIRATES COMBINATION ANTIBODY THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 272. UNITED ARAB EMIRATES COMBINATION ANTIBODY THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 273. UNITED ARAB EMIRATES COMBINATION ANTIBODY THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 274. UNITED KINGDOM COMBINATION ANTIBODY THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 275. UNITED KINGDOM COMBINATION ANTIBODY THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 276. UNITED KINGDOM COMBINATION ANTIBODY THERAPY MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 277. UNITED KINGDOM COMBINATION ANTIBODY THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 278. UNITED KINGDOM COMBINATION ANTIBODY THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 279. UNITED KINGDOM COMBINATION ANTIBODY THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 280. COMBINATION ANTIBODY THERAPY MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 281. COMBINATION ANTIBODY THERAPY MARKET, FPNV POSITIONING MATRIX, 2023